

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act

Item 8.01

Other Events.

On December 6, 2017, VistaGen Therapeutics, Inc. (the "Company") announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 9,834,801 related to certain methods of production for AV-101, the Company's lead product candidate. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1, and is incorporated herein by reference.

Item 9.01

Financial Statements and Exhibits.

See Exhibit Index.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

VistaGen Therapeutics, Inc.

Date: December 6, 2017 By: /s/ Shawn K. Singh
Shawn K. Singh
Chief Executive Officer

EXHIBIT INDEX

Exhibit No. Description

99.1 Press release issued by VistaGen Therapeutics Inc., dated December 6, 2017.